756 Eli Lilly and Company $LLY Shares Purchased by Verdence Capital Advisors LLC

Posted by Brian Himes on Oct 29th, 2026

Eli Lilly and Company logo Verdence Capital Advisors LLC grew its stake in Eli Lilly and Company (NYSE:LLY – Free Report) by 10.5% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,979 shares of the company’s stock after purchasing an additional 756 shares during the quarter. Verdence Capital Advisors LLC’s holdings in Eli Lilly and Company were worth $9,233,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Mill Capital Management LLC grew its position in Eli Lilly and Company by 0.3% in the 3rd quarter. Mill Capital Management LLC now owns 25,509 shares of the company’s stock worth $29,516,000 after purchasing an additional 87 shares in the last quarter. Geneva Partners LLC increased its stake in Eli Lilly and Company by 488.0% in the 3rd quarter. Geneva Partners LLC now owns 8,444 shares of the company’s stock valued at $9,770,000 after buying an additional 7,008 shares during the last quarter. Plimoth Trust Co. LLC increased its stake in Eli Lilly and Company by 2.4% in the 3rd quarter. Plimoth Trust Co. LLC now owns 9,421 shares of the company’s stock valued at $10,901,000 after buying an additional 220 shares during the last quarter. B.O.S.S. Retirement Advisors LLC lifted its position in shares of Eli Lilly and Company by 2.9% during the 3rd quarter. B.O.S.S. Retirement Advisors LLC now owns 356 shares of the company’s stock worth $412,000 after buying an additional 10 shares in the last quarter. Finally, Deroy & Devereaux Private Investment Counsel Inc. lifted its position in shares of Eli Lilly and Company by 16.6% during the 3rd quarter. Deroy & Devereaux Private Investment Counsel Inc. now owns 1,753 shares of the company’s stock worth $2,028,000 after buying an additional 250 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

Positive Sentiment: Retatrutide produced a major clinical win over Ozempic. In a Phase 3 head-to-head trial, the investigational drug delivered average weight loss of approximately 44–47 pounds, or 20%–21%, after 80 weeks, compared with about 21 pounds for Ozempic. Retatrutide also reduced A1C by 2.2% versus 1.8% for Ozempic 2 mg. The results strengthen Lilly’s long-term position in the highly competitive obesity-drug market, although retatrutide is not yet approved. Lilly retatrutide trial results
Positive Sentiment: A federal judge rejected Novo Nordisk’s effort to block Lilly’s weight-loss drug advertising, finding insufficient evidence of meaningful sales harm. The ruling preserves Lilly’s ability to market Zepbound and its obesity portfolio using the challenged campaign. Court rejects Novo advertising challenge
Positive Sentiment: Lilly is broadening its pipeline beyond GLP-1 medicines, with Kisunla in neuroscience and Taltz and newer therapies in immunology expected to support growth. The company also licensed the SpeechDx Alzheimer’s dataset to advance speech-based disease markers. Lilly neuroscience and immunology outlook
Positive Sentiment: Bernstein raised its Lilly price target to $1,450 from $1,385, reflecting continued confidence in the company’s growth outlook. Lilly also declared a quarterly dividend of $1.73 per share.
Neutral Sentiment: Patrik Jonsson will retire as head of Lilly International at year-end 2026, with Ilya Yuffa taking over the expanded Lilly Global Markets role on January 1, 2027. The transition is planned, but investors may monitor execution as the company consolidates its global commercial structure. Lilly leadership transition
Negative Sentiment: Investors face substantial earnings-event risk ahead of Thursday’s report. Analysts expect roughly $6.67 in earnings per share and $22.62 billion in revenue, while options markets imply a potentially large post-earnings move. Reports that recent EPS estimates have fallen sharply add to caution.
Negative Sentiment: About 16% of employers are reportedly considering reducing coverage for weight-loss medicines. Any broader reimbursement pullback could pressure demand for Zepbound and limit the market’s near-term growth assumptions. Employer weight-loss drug coverage concerns
Negative Sentiment: Two Massachusetts hospitals joined a lawsuit alleging Lilly’s digital tools may put patient privacy at risk. The claims remain unresolved, but adverse findings could create legal, regulatory, and reputational costs. Patient privacy lawsuit

Insider Transactions at Eli Lilly and Company

In related news, EVP Patrik Jonsson sold 6,500 shares of the company’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the completion of the transaction, the executive vice president directly owned 54,147 shares in the company, valued at approximately $63,628,139.70. The trade was a 10.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald Zakrowski sold 2,000 shares of Eli Lilly and Company stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the sale, the chief accounting officer directly owned 1,526 shares of the company’s stock, valued at approximately $1,808,325.26. This trade represents a 56.72% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 13,500 shares of company stock valued at $15,958,170. Insiders own 0.14% of the company’s stock.

Analyst Ratings Changes

LLY has been the topic of a number of research analyst reports. TD Cowen restated a “buy” rating and issued a $1,250.00 target price on shares of Eli Lilly and Company in a research note on Tuesday, September 22nd. Berenberg Bank set a $1,400.00 target price on Eli Lilly and Company and gave the company a “buy” rating in a report on Tuesday, September 15th. BMO Capital Markets reaffirmed an “outperform” rating on shares of Eli Lilly and Company in a research report on Thursday, October 1st. Bank of America lifted their price target on Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the stock a “buy” rating in a report on Friday, July 10th. Finally, UBS Group set a $1,376.00 price objective on Eli Lilly and Company in a research report on Friday, August 7th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $1,320.25.

View Our Latest Research Report on Eli Lilly and Company

Eli Lilly and Company Trading Up 0.6%

Shares of LLY stock opened at $1,289.36 on Thursday. The stock has a market capitalization of $1.21 trillion, a price-to-earnings ratio of 43.27, a PEG ratio of 1.71 and a beta of 0.46. The company’s fifty day simple moving average is $1,192.52 and its two-hundred day simple moving average is $1,089.35. Eli Lilly and Company has a 1 year low of $809.63 and a 1 year high of $1,321.21. The company has a debt-to-equity ratio of 1.41, a current ratio of 1.35 and a quick ratio of 1.00.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, beating the consensus estimate of $6.40 by $1.98. The firm had revenue of $22.97 billion for the quarter, compared to analysts’ expectations of $20.82 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%. The company’s revenue was up 47.7% on a year-over-year basis. During the same period in the prior year, the business posted $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, analysts anticipate that Eli Lilly and Company will post 33.22 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date of this dividend is Friday, November 13th. Eli Lilly and Company’s payout ratio is currently 23.22%.

About Eli Lilly and Company

(Free Report)

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company’s portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer’s disease.